drugset
drugset / Trial / NCT00052520

Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation

NCT00052520 ↗

Phase 1/2 Completed 37 enrolled Fred Hutchinson Cancer Center National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment

Summary

This phase I/II trial is studying the side effects of biological therapy and to see how well it works in treating patients with advanced myelodysplastic syndrome, chronic myeloid leukemia, acute myeloid leukemia, or acute lymphoblastic leukemia. Biological therapies, including immunotherapy, can potentially be used to stimulate the immune system and stop cancer cells from growing. Immunotherapy given to patients who have undergone donor stem cell transplantation may be a way to eradicate remaining cancer cells

Timeline

Start
2002-09
Primary completion
2011-04
Completion
2013-06

Drugs

EvaluationDrugModalityDoseRoute
Subject CD8-positive WT1 gene-specific CTL clones Cell therapy — Intravenous
Background aldesleukin Protein / enzyme biologic — Subcutaneous

Indications

B-cell adult acute lymphocytic leukemia B-cell childhood acute lymphoblastic leukemia T-cell adult acute lymphocytic leukemia T-cell childhood acute lymphocytic leukemia acquired polycythemia vera acute myeloid leukemia with 11q23 abnormalities acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) acute myeloid leukemia with t(8;21)(q22;q22) translocation childhood acute myeloid leukemia childhood myelodysplastic syndrome chronic myeloid leukemia chronic myelomonocytic leukemia essential thrombocythemia myelodysplastic syndrome with excess blasts refractory anemia with excess blasts in transformation